RegeneRx Announces Positive Phase III Results for RGN-259 in Dry Eye

November 17, 2017: By Jon Swedien

RegeneRx Biopharmaceuticals’ proposed dry eye treatment, RGN-259, showed statistically significant improvement over placebo in its ARISE-2 Phase III clinical study, the Rockville, Maryland company reported Oct. 31.

RGN-259, a Thymosin beta 4 (Tβ4)-based sterile and preservative-free eye drop, is as a novel treatment candidate for dry eye and neurotrophic keratitis (NK), and other corneal diseases, RegeneRx said.

The ARISE-2 trial was sponsored by ReGenTree, a US joint venture company owned by GtreeBNT, a bio venture company in South Korea, and RegeneRx.

The trial investigated the safety and efficacy of RGN-259 for the treatment of the signs and symptoms of dry eye syndrome in 601 patients.

RGN-259 (0.1%) demonstrated a number of statistically significant improvements in both signs and symptoms, while showing excellent safety, comfort, and tolerability profiles, ReGenTree said.

For example, the RGN-259-treated group saw a statistically significant reduction in ocular discomfort at day 15 compared with placebo (p=0.0149) in a change from baseline, ReGenTree said.

ReGenTree president and CEO Won S. Yang said the company plans to meet with the US FDA to discuss the ARISE-2 findings.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Refocus Completes PMA Application for VisAbility as Treatment for Presbyopia

Novaliq’s NovaTears+Omega-3 Approved in Europe for Dry Eye

CooperVision Acquires Paragon Vision Sciences for $80 Million

AYOXXA Biosystems Launches Test for Biomarkers in Retinal Disease

Glaukos Announces New Patent for Glaucoma Stent Implanted in Schlemm’s Canal

Fortress Biotech Forms Tamid Bio Subsidiary; Lead Candidate is Ophthalmic Gene Therapy for MPS I

Samsung Launches App that Adjusts QLED TV Settings for Color-blind Viewers

Solar Eclipse Burns Crescent Wound in Woman’s Unprotected Retina

US Judge Refuses to Dismiss Allergan Suit against Imprimis

BioLight Sells IOPtima to Chengdu Kanghong Pharmaceutical Group for $56 Million

Regeneron Ending Eylea, Nesvacumab Combo Program

UK Retinal Drugmaker Exonate Forms Clinical Advisory Board

US FDA Approves RxSight’s Light Adjustable Lens and Light Delivery Device

EMA to Move to Amsterdam due to Brexit

First Subject Dosed in Nevakar’s Phase III Trial of NVK-002 for Myopia in Children

ProQR Doses First Patient in Phase I/II Trial for Leber’s Congenital Amaurosis 10

Aston EyeTech Raises $6.6 Million in Series A Equity Round

Ellex Raises $17.7 Million in Private Placement

Genentech’s Lampalizumab Fails Second Phase III Study in Geographic Atrophy

Judge Declares Mistrial in Corruption Trial of Melgen, Menendez

Coming soon

2017 Dry Eye Products Report: A Global Market Analysis for 2016 to 2022